Crescent Biopharma, Inc. Common Stock (CBIO) is a publicly traded Healthcare sector company. As of July 15, 2026, CBIO trades at $14.90 with a market cap of $432.65M and a P/E ratio of -193.44. CBIO moved -2.29% today. Year to date, CBIO is +29.05%; over the trailing twelve months it is +19.57%. Its 52-week range spans $8.72 to $27.41. Analyst consensus is strong buy with an average price target of $31.00. Rallies surfaces CBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for CBIO combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $14.90 |
| Market Cap | $432.65M |
| P/E Ratio | -193.44 |
| EPS | $-0.08 |
| Dividend Yield | 0.00% |
| 52-Week High | $27.41 |
| 52-Week Low | $8.72 |
| Volume | 53.47K |
| Avg Volume | 0 |
| Revenue (TTM) | $117.05M |
| Net Income | $-1.39M |
| Gross Margin | 95.09% |
7 analysts cover CBIO: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $31.00.